|
|
Hip fracture after stroke is an increasingly recognized problem. Measures to prevent bone loss and preserve bone architecture have not been part of stroke management thus far. Because rapid bone loss is a risk factor for fracture, we belie ve that a randomized, placebo-controlled trial of intravenous bisphophonates given in the early phase of stroke rehabilitation is indicated. |
|